ХЭНВУД Джеральдин А. (US),МЭК Рэндалл Дж. (US),ШЭРР Кристофер Т. (US),КОУЛЕНГ Мл. Джон Дж. (US)
申请号：
RU2012133969/15
公开号：
RU2012133969A
申请日:
2011.01.07
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method for treating or preventing pain, vklyuchayuschiynanesenie to mammalian skin a composition comprising a dose of dexmedetomidine or a pharmaceutically acceptable salt or prodrug thereof in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable salt or prodrug dexmedetomidine is absorbed through the skin and causes analgesia without sedation deystviya.2. A method according to claim 1, wherein said dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is in the range between about 0.05 mg / kg and about 15 mg / kg, and wherein said mammal is chelovek.3. A method according to claim 2, wherein said mammal is a human and said transdermal dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is in the range between about 100 and about 1500 micrograms mkg.4. A method according to claim 3, wherein the plasma Sdeksmedetomidina after absorption from the transdermal system, and the circulatory system of said person is less than about 0.30 ng / ml.5. A method according to claim 2, wherein deposition step comprises topical application of the pharmaceutical composition to the skin at least one of the body parts such as legs, arms, the abdomen, the chest, groin, neck, back and plechi.6. A method according to claim 5, wherein the application step comprises applying a cream, lotion or gel pharmaceutical composition to the skin mlekopitayuschego.7. A method according to claim 6, wherein the application step does not require a dressing cover the skin after administration of the pharmaceutical composition to the skin mlekopitayuschego.8. A method according to claim 2, wherein for at least 6 hours immediately after the application of a pharmaceutical composite1. Способ лечения или предотвращения боли, включающийнанесение на кожу млекопитающего композиции, содержащей дозу дексмедетомидина или его фармацевтически приемлемой соли или пролекарства в фармацевтически приемлемом носителе,где фармацевтически приемлемая соль или п
